Pharmacognosy intro
Hericium erinaceus (Bull.) Pers., family Hericiaceae, is a tooth fungus known as Lion's Mane, Bearded Tooth, or Yamabushitake. Both the fruiting body and mycelium are used, but their compound profiles differ substantially. The fruiting body contains hericenones C, D, E, F, G, and H. The mycelium contains erinacines A, B, C, E, F, H, I, and S, which are cyathane diterpenoids. Novel compounds include hericene A and NDPIH (N-de phenylethyl isohericerin). Additional bioactives include beta-glucan polysaccharides and ergothioneine, a potent intracellular antioxidant with a dedicated transporter (OCTN1/SLC22A4). Quality extracts standardize to >1% combined hericenones and erinacines with >25% polysaccharides. Erinacines, particularly erinacine A, cross the blood-brain barrier and stimulate de novo synthesis of nerve growth factor (NGF) in astrocytes through ERK1/2 pathway activation leading to NGF gene transcription. Hericenones C, D, and E stimulate NGF synthesis in vitro but with lower potency and uncertain BBB penetration. Martinez-Marmol et al. (2023, J Neurochem) identified hericene A as a novel compound activating a pan-neurotrophic signaling pathway independent of TrkB receptor, promoting neurite outgrowth and axonal branching through mechanisms distinct from classical neurotrophins. NDPIH promotes neuronal projection through additional novel pathways. The neurotrophic cascade promotes hippocampal neurogenesis (increased BrdU+/NeuN+ cells in dentate gyrus), 2-3x enhancement of neurite outgrowth and branching complexity in PC12 cells, BDNF upregulation, and myelin synthesis support in Schwann cells. Mori et al. (2009, Phytother Res, DOI: 10.1002/ptr.2634) conducted the landmark double-blind, placebo-controlled RCT: n=30 Japanese adults (50-80 years) with mild cognitive impairment received 3g/day for 16 weeks. Significant improvement on Hasegawa Dementia Scale-Revised at weeks 8, 12, and 16 versus placebo (p<0.05). Cognitive gains reversed 4 weeks after discontinuation, suggesting ongoing supplementation is required. Nagano et al. (2010, Biomed Res) showed reduced depression and anxiety scores in menopausal women (n=30, 4-week RCT). Human clinical trials remain few and small. Product variability between fruiting body, mycelium, and mycelium-on-grain preparations introduces significant confounding, as mycelium-on-grain products may contain 50-70% starch with minimal active compounds.